{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-108759","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2023-10-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.001210+00:00","generated_at":"2026-06-10T01:21:45.301412+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Acura receives $250K loan from controlling shareholder; warns cash only covers ops through late Nov 2023","bullets":["Loan from AD Pharma (owns ~66% of Acura) increases aggregate principal to $4.42M at 5.25% interest, matures Dec 31, 2023.","Proceeds expected to fund operations only through late November 2023; no assurance of additional financing.","If unable to secure additional financing, company may need to scale back operations or seek bankruptcy protection.","AD Pharma is controlled by Mr. Schutte, who also directly owns ~14% of Acura's outstanding common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-108759","json":"https://secwatch.observer/filing/0001104659-23-108759.json","markdown":"https://secwatch.observer/filing/0001104659-23-108759.md","text":"https://secwatch.observer/filing/0001104659-23-108759.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465923108759/0001104659-23-108759-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465923108759/tm2328285d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:21:45.301412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e9660117765c27d379cdee9110759435b0d2f67f","claim":"ACURA PHARMACEUTICALS, INC incurred loan of $250,000 with Abuse Deterrent Pharma, LLC at 5.25% maturing December 31, 2023.","evidence_excerpt":"On October 11, 2023 we received a $250,000 loan from Abuse Deterrent Pharma, LLC (\"AD Pharma\"). This loan combined with previous loans made to the Company and with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now totals $4,419,279, bears interest at 5.25% and matures on December 31, 2023, at which time all principal and interest is due.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465923108759/0001104659-23-108759-index.htm","confidence":0.98,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$250,000"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Maturity","value":"December 31, 2023"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}